Trial document
This study has been imported from ClinicalTrials.gov without additional data checks.
DRKS00007239
Trial Description
Title
Phase III Study on Alternative Dosing Regimens in the Pharmacotherapy of Mild to Moderate Insomnia
Trial Acronym
ALPHASOM
URL of the Trial
[---]*
Brief Summary in Lay Language
The purpose of this study is to evaluate whether drug efficiency of zolpidem and
amitriptyline can be conditioned according to learning theory in patients with primary
insomnia.
Brief Summary in Scientific Language
Previous research has shown that repeated drug treatments can be regarded as conditioning
processes. Sleep disorders are especially of interest to be investigated under the
perspective of conditioning with drugs, since sleep quality can be defined both in terms of
subjective ratings (self-rated sleep quality parameters) and objective measures (via
polysomnographic assessment PSG; e.g., total sleep time, sleep onset, sleep architecture).
By using two different drugs (zolpidem, amitriptyline) that modulate sleep differentially,
the investigators intend to implement a conditioning paradigm in sleep disorders
dissociating conditioning effects on subjective and objective sleep parameters. Both drugs
should affect objective and subjective sleep parameters positively, while only amitriptyline
should modulate the objectively assessed sleep architecture by REM-suppression (latency of
REM-sleep onset, percentage of REM-sleep).Patients with mild to moderate insomnia will
undergo a classical conditioning paradigm with one of two study medications: amitriptyline
or zolpidem. After an acquisition period and a wash-out period, conditioned sleep changes
are assessed in an evocation trial. During a second treatment phase of 7 days, patients
receive different doses of amitriptyline (between 0mg and 50mg per night) or zolpidem
(between 0mg and 5mg per night) to evaluate alternative dosing regimens in the
pharmacotherapy of mild to moderate Insomnia.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00007239
- 2015/05/06
- 2014/04/24
- yes
- [---]*
- [---]*
Secondary IDs
- 2013-003229-27
- NCT02139098 (ClinicalTrials.gov)
- FOR1328-SP8 (Philipps University Marburg Medical Center)
- 2013-003229-27
Health Condition or Problem studied
- Insomnia
- F51.0 - Nonorganic insomnia
Interventions/Observational Groups
- Drug: Amitriptyline
- Drug: Zolpidem
- Drug: Amitriptyline
- Drug: Placebo
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Blinded
- patient/subject, caregiver, investigator/therapist, assessor
- Placebo, Active control
- Treatment
- Parallel
- III
- [---]*
Primary Outcome
- Objective Total Sleep Time; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Objective Sleep Onset Latency; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Self-reported Total Sleep Time; time frame: Change from baseline to day 10 after first medication intake; assessed by sleep diary
- Self-Reported Sleep Onset Latency; time frame: Change from baseline to day 10 after first medication intake; assessed by sleep diary
Secondary Outcome
- Percentage of REM sleep; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- REM onset latency; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Objective Sleep Efficiency; time frame: Change from baseline to day 17 after first medication intake; assessed by actigraphy
- Objective Total Sleep Time; time frame: Change from baseline to day 17 after first medication intake; assessed by actigraphy
- Self-Reported Total Sleep Time; time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary
- Self-reported Sleep Onset Latency (min); time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary
- Self-reported Sleep Onset Latency (evaluation); time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary
Countries of Recruitment
- Germany
Locations of Recruitment
Recruitment
- [---]*
- 2014/05/31
- 150
- [---]*
- [---]*
Inclusion Criteria
- Both, male and female
- 18 Years
- 69 Years
Additional Inclusion Criteria
1. age between 18 years to 69 years
2. fluent in German language
3. provide written informed consent
4. ability to understand the explanations and instructions given by the study physician
and the investigator
Exclusion Criteria
1. Sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome,
narcolepsy, substance-induced insomnia)
2. Contraindications to study medication intake according to the information sheet for
health professionals (Summary of medicinal Product Characteristics, SmPC;
Fachinformation in Germany) assessed by physical examination (including ECG) and
medical history
- allergies to amitriptyline hydrochloride or any of its ingredients
- allergies to zolpidem or any of its ingredients
- acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic
drug
- urinary retention
- delirium
- untreated closed-angle glaucoma
- prostatic hyperplasia
- pyloric stenosis
- paralytic ilius
- suicidal thoughts
- liver/ kidney/ pulmonary insufficiency
- myasthenia gravis
- hypokalemia
- bradycardia
- coronary heart disease, cardiac arrhythmias, long QT syndrome or other
clinically relevant cardiac disorders
- increased risk of seizures/ history of seizures
- substance dependence syndrome/ history of substance dependence syndrome
3. Allergies to ingredients of placebo or novel-tasting drink (CS)
4. currently pregnant (verified by urine pregnancy test) or lactating
5. patients scoring ≥12 on the Epworth Sleepiness Scale
6. patients scoring below 8 or above 21 on the Insomnia Severity Index
7. patients suffering from a mental disorder as verified by the SCID (major depression;
psychosis; brain injury; substance abuse or dependency syndrome during the last 6
months before V1)
8. nicotine consumption > 10 cigarettes/day
9. unwillingness to refrain from alcohol consumption throughout the study
10. Concomitant medication interfering with study medication intake due to potential
interactions (all psychotropic medication including analgetics and muscle relaxants,
hypericum derivatives; antihypertensives; anti-arrhythmic agents; antibiotics;
cisaprid; anti-malaria drugs; diuretics; imidazole antifungals; cumarin derivatives;
antihistaminics; calcium channel blockers; medications that enlarge the QT interval
or may lead to hypokalemia)
11. change in concomitant medication regime during the last 2 weeks prior to visit 1 or
after randomization
12. intake of psychotropic medication during the last 3 months
13. participation in any other clinical trial 3 months prior to visit 1
14. women of childbearing age not using 2 highly effective contraceptive methods
15. employee of the Sponsor or the principal investigator
Addresses
-
start of 1:1-Block address primary-sponsor
- Philipps University Marburg Medical Center
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address other
- Department of Pneumology, Medical School, Philipps University Marburg
end of 1:1-Block address otherstart of 1:1-Block address contact other- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address other
- Institute of Laboratory Medicine, Pathobiochemistry and Molecular Diagnostics, Philipps University Marburg
end of 1:1-Block address otherstart of 1:1-Block address contact other- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address other
- University Medical Center, Johannes Gutenberg University Mainz
end of 1:1-Block address otherstart of 1:1-Block address contact other- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address other
- Philipps University Marburg Coordination Centre for Clinical Trials
end of 1:1-Block address otherstart of 1:1-Block address contact other- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address scientific-contact
- Clinical Psychology and Psychotherapy, Department of Psychology, Philipps University Marburg
- Winfried Rief, Prof. Dr.
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Bettina K Doering, Dr.
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- +49-6421-28 23 657
- [---]*
- bettina.doering at staff.uni-marburg.de
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- [---]*
- 1
- 2014/11/05